Search

Search Results

• 

  PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems^1|5, A.E. Van Diepen^1|2|6, EN. Dekker⁷, Q.P. Janssen⁷, J.L. Van Dam⁷, N. Michiels⁸, C.W.F. Van Eijck⁹, K.E.P.E. Hermans^1|2, B.A. Bonsing⁸, K.P. Bosscha¹⁰, S.A.W. Bouwense^11|12, O. R. Busch^13|14, H. Ten Cate^4|5|15|16, P.P.L.O. Coene¹⁷, C.H.J. Van Eijck⁷, N. Van Es^18|19, E. Van Der Harst¹⁷, I.H.J.T. De Hingh²⁰, T.M. Karsten²¹, G. Kazemier^13|14, M.B. Van Der Kolk²², B. De Laat^3|5, M.S.L. Liem²², J.S.D. Mieog⁸, V.B. Nieuwenhuijs²⁴, G.A. Patijn²⁴, M. Roest³, H.C. Van Santvoort²⁵, L. Valkenburg-Van Iersel^1|2, R. F. De Wilde⁷, F. Wit²⁶, B.M. Zonderhuis^13|14, M.G. Besselink^13|14, M.Y.V. Homs⁶, G. Van Tienhoven^14|27, J. W. Wilmink^14|28, B. Groot Koerkamp⁷, J. De Vos-Geelen^1|2 | ¹Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; ²GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; ³Synapse Research Institute, Department of Functional Coagulation, Maastricht; ⁴Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; ⁵Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; ⁶Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; ⁷Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; ⁸Leiden University Medical Center, Department of Surgery, Leiden; ⁹Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; ¹⁰Jeroen Bosch Hospital, Department of Surgery, Den Bosch; ¹¹Maastricht University Medical Center, Department of Surgery, Maastricht; ¹²Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; ¹³Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; ¹⁴Cancer Center Amsterdam; ¹⁵Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; ¹⁶Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; ¹⁷Maasstad Hospital, Department of Surgery, Rotterdam; ¹⁸Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; ¹⁹Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; ²⁰Catharina Hospital, Department of Surgery, Eindhoven; ²¹OLVG, Department of Surgery, Amsterdam; ²²Radboud University Medical Center, Department of Surgery, Nijmegen; ²³Medisch Spectrum Twente, Department of Surgery, Enschede; ²⁴Isala Oncology Center, Department of Surgery, Zwolle; ²⁵Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; ²⁶Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; ²⁷Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; ²⁸Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.507

  3

  PDF: 0
• 

  PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven^1|9, E. Van Gansewinkel^5|10, J. De Bruijne², F. Eskens³, D. De Groot⁴, K. Hermans⁵, N. Mohammad⁶, F. Van Vilsteren⁷, C. Verslype⁸, W. Moris⁹, M. Roest¹⁰, B. De Laat¹⁰ , J. De Vos-Geelen⁵, M. Kramer^1|9 | ¹Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ²Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; ³Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; ⁴Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; ⁵Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; ⁶Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; ⁷Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; ⁸Digestive Oncology, University Hospitals Leuven, Belgium; ⁹Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; ¹⁰Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.554

  2

  PDF: 0
• 

  PO04 | FIBRIN CLOT SHIELDS PROMOTE CLONAL SELECTION IN CANCER CELLS: PROCOAGULANT ACTIVITY AND SURVIVAL OF CLOT-EMBEDDED CELLS. A NOVEL TUMOR MICROENVIRONMENT MODEL M.A. Baghdadi^1|2, E. Mbemba¹, P. Las Casa¹, P. Van Dreden^1|3, N. Saleem^1|4, J. Fareed⁴, P. Kempaiah⁴, M. Sabbah¹, G. Gerotziafas^1|4 | ¹Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology, Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris, France; ²Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; ³Diagnostica Stago, Gennevilliers, France; ⁴Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.500

  2

  PDF: 0
• 

  PO02 | SYNERGISTIC INTERACTION OF ENDOTHELIAL AND CANCER CELLS IN THE FORMATION AND STRUCTURE OF THE FIBRIN CLOT SHIELDS M.A. Baghdadi^1|2, E. Mbemba¹, P. Las Casa¹, P. Van Dreden^1|3, N. Saleem^1|4, J. Fareed⁴, P. Kempaiah⁴, M. Sabbah¹, G. Gerotziafas^1|4 | ¹Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; ²Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; ³Diagnostica Stago, clinical research, Gennevilliers, France; ⁴Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.498

  3

  PDF: 1
• 

  OC11 | COMPLEXITIES IN MANAGING ANTITHROMBOTIC THERAPY IN PATIENTS WITH CANCER APPROACHING END-OF-LIFE: A MIXED METHOD INTEGRATION USING JOINT DISPLAY ANALYSIS E. Baddeley¹, L. Van’t Walderveen², H. Enggaard³, M. Søgaard⁴, D. Abbel², S. Cannegieter², M. Edwards¹, C. Font⁵, J. Goedegebuur², F.A. Klok², K.J. Lifford¹, I. Mahé⁶, S.P. Mooijaart², S.I.R. Noble¹, M. Pearson⁷, K. Seddon¹, S. Sivell¹, S. Szmit⁸, S Trompet², A.A. Højen⁴ | ¹Cardiff University, Cardiff, UK; ²Leiden University Medical Center, Leiden, The Netherlands; ³Aalborg University Hospital, Aalborg, Denmark; ⁴Aalborg University and Aalborg University Hospital, Aalborg, Denmark; ⁵Hospital Clinic Barcelona, Barcelona, Spain; ⁶Paris Cité Université, Paris, France; ⁷Hull York Medical School, Hull, UK; ⁸Centre of Postgraduate Medical Education, Warsaw, Poland

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.494

  1

  PDF: 0
• 

  PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY G. Gerotziafas^1|3|4|5, S. Allakhverdieva⁶, P. Henrique Fernandes Do Carmo Las Casa¹, P. Van Dreden^1|2, J. Fareed³, N. Lomakin⁶ , I. Zotova⁶, L. Buryachkovskaya⁷ | ¹Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; ²Clinical Research, Diagnostica Stago, Gennevilliers, France; ³Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; ⁴Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ⁵VAS-European Independent Foundation in Angiology/Vascular Medicine Milan, Italy; ⁶Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; ⁷Federal State Budgetary Institution «National Medical Research Centre of Cardiology Named After Academician E. I. Chazov» of the Ministry of Health of the Russian Federation, Moscow, Russia

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.546

  1

  PDF: 0
• 

  OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou¹, I. Diamandoulaki², P. Baglaridis¹, P. Las Casa³, P. Van Dreden⁴, K. Toutouzas¹, G. Gerotziafas^4|5 | ¹First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; ²Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; ³Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; ⁴Diagnostica Stago, clinical research, Gennevilliers, France; ⁵Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.486

  7

  PDF: 1
• 

  PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas^1|4, Y. Mitrou⁵, M. Marchetti⁶, P. Las Casa¹, A. Tafur⁷, V. Bitsadze³, J. Khizroeva³, D. Taizhanova⁸, D. Antic⁹, C. Frére¹⁰, A. Makatsariya³, L. Garderet^1|11, A. Escargueil¹, C. Ay¹², N. Lomatkin¹³, Z. Tazi-Mezalek¹⁴, M. Sassi¹⁵, M. Catalano^4|16, J. Gligorov^1|17, J. Caprini¹⁸, P. Van Dreden^1|19, J. Fareed², A. Falanga⁶ | ¹Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; ²Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; ³Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ⁴VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; ⁵Department of Phylosophy, National and Kapodistrian University of Athens, Greece; ⁶Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; ⁷Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; ⁸Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; ⁹Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; ¹⁰Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; ¹¹Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; ¹²Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; ¹³Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; ¹⁴Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; ¹⁵Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; ¹⁶Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; ¹⁷Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; ¹⁸Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; ¹⁹Clinical Research, Diagnostica Stago, Gennevilliers, France

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.516

  1

  PDF: 0
• 

  Thromboprophylaxis in primary brain cancer

  Eva N. Hamulyák, Barbara A. Hutten, Nick van Es

  16-04-2026

  https://doi.org/10.4081/btvb.2026.455

  0

  PDF: 0
• 

  PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Langholm¹, N.H. Eide¹, K. Hveem^2|3|4, N. Van Es^5|6, V.M. Morelli^1|7, S.K. Braekkan^1|7, J.B. Hansen^1|7 | ¹Thrombosis Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; ²HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; ³HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; ⁴Department of Research, St. Olav University Hospital, Trondheim, Norway; ⁵Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; ⁶Amsterdam Cardiovascular Sciences Pulmonary Hypertension and Thrombosis Amsterdam, the Netherlands; ⁷Thrombosis Research Center, Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.505

  1

  PDF: 0